Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Депрессия при онкологических заболеваниях: подходы к диагностике и терапии

Литература

  1. Депрессия и риск развития соматических заболеваний: руководство для врачей / под ред. Н. Г. Незнанова, Г. Э. Мазо, А. О. Кибитова. М., 2018. 248 с.
  2. Павловский А. В., Моисеенко В. Е., Попов С. А. и соавт. Аффективные нарушения как предиктор риска развития онкологических заболеваний на примере злокачественных опухолей поджелудочной железы // Медицинский алфавит. 2020; 29: 44–47.
  3. Рукавишников Г. В., Мазо Г. Э. Шизофрения и онкологические заболевания: в поисках решения «эпидемиологической головоломки» // Социальная и клиническая психиатрия. 2019; 29 (4): 84–89.
  4. Рукавишников Г. В., Незнанов Н. Г., Мартынов А. И., Мазо Г. Э. Терапия депрессии у пациентов с коморбидными соматическими заболеваниями // Терапия. 2020; 6 (3): 76–83.
  5. Breitbart W., Rosenfeld B., Tobias K. et al. Depression, cytokines, and pancreatic cancer // Psychooncology. 2014; 23 (3): 339–345.
  6. Botwinick I. C., Pursell L., Yu G. et al. A biological basis for depression in pancreatic cancer // HPB (Oxford). 2014; 16: 740–743.
  7. Butow P. N., Hiller J. E., Price M. A. et al. Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer // J. Psychosom. Res. 2000; 49: 169–181.
  8. Chan C., Lin H. J., Lin J. Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane // Int. J. Oncol. 2008; 33: 415–419.
  9. Chida Y., Hamer M., Wardle J. et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? // Nat. Clin. Pract. Oncol. 2008; 5: 466–475.
  10. Dalton S. O., Boesen E. H., Ross L. et al. Mind and cancer: do psychological factors cause cancer? // Eur. J. Cancer. 2002; 38: 1313–1323.
  11. Depression and Cancer / ed. by D. W. Kissane, M. Maj, N. Sartorius. Oxford, 2011. 258 p.
  12. Desmarais J. E., Looper K. J. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6 // J. Clin. Psychiatry. 2009; 70 (12): 1688–97.
  13. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015; 136 (5): E359–E386.
  14. Fox C. M., Harper A. P., Hyner G. C. et al. Loneliness, emotional repression, marital quality, and major life events in women who develop breast cancer // J. Community Health. 1994; 19: 467–482.
  15. Friberg S., Mattson S. On the growth rates of human malignant tumors: implications for medical decision making // J. Surg. Oncol. 1997; 65: 284–297.
  16. Garssen B. Psychological factors and cancer development: evidence after 30 years of research // Clin. Psychol. Rev. 2004; 24: 315–338.
  17. Green A. I., Austen C. P. Psychopathology of pancreatic cancer. A psychobiologic probe // Psychosomatics. 1993; 34: 208–221.
  18. Gross A. L., Gallo J. J., Eaton W. W. Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample // Cancer Causes Control. 2010; 21: 191–199.
  19. Hahn R. C., Petitti D. B. Minnesota Multiphasic Personality Inventory-rated depression and the incidence of breast cancer // Cancer. 1988; 61 (4): 845–848.
  20. Huang T., Poole E. M., Okereke O. I. et al. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies // Gynecol. Oncol. 2015; 139 (3): 481–486.
  21. Inagaki M., Yoshikawa E., Kobayakawa M. et al. Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis // J. Affect Disord. 2007; 99: 231–236.
  22. Jacobs J. R., Bovasso G. B. Early and chronic stress and their relation to breast cancer // Psychol. Med. 2000; 30: 669–678.
  23. Jemal A., Bray F., Center M. M. et al. Global cancer statistics // CA Cancer J. Clin. 2011; 61 (2): 69–90.
  24. Kim-Fuchs C., Le C. P., Pimentel M. A. et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment // Brain Behav. Immun. 2014; 40: 40–47.
  25. Kroenke C. H., Bennett G. G., Fuchs C. et al. Depressive symptoms and prospective incidence of colorectal cancer in women // Am. J. Epidemiol. 2005; 162: 839–848.
  26. Lemogne C., Consoli S. M., Melchior M. et al. Depression and the Risk of Cancer: A 15-year Follow-up Study of the GAZEL Cohort // Am. J. Epidemiol. 2013; 178 (12): 1712–1720.
  27. Leong A. S. Y., Siavotinek A. H., Deakin E. J. The pathology of experimental chronic fibrosing pancreatitis: light microscopic and ultrastructural observations // Pathology. 1982; 14: 363–368.
  28. Li R., Hou J., Xu Q. et al. High level interleukin-6 in the medium of human pancreatic cancer cell culture suppresses production of neurotransmitters by PC 12 cell line // Metab. Brain Dis. 2012; 27: 91–100.
  29. Liebowitz M. R., Gorman J. M., Fyer A. J. et al. Lactate provocation of panic attacks: II. Biochemical and physiological findings // Arch. Gen. Psychiatry. 1985; 42: 709–719.
  30. Malhi G. S., Byrow Y., Fritz K. et al. Mood disorders: neurocognitive models // Bipolar Disord. 2015; 17 (2): 3–20.
  31. McGee R., Williams S., Elwood M. Depression and the development of cancer: a meta-analysis // Soc. Sci. Med. 1994; 38: 187–192.
  32. McKenna M. C., Zevon M. A., Corn B. et al. Psychosocial factors and the development of breast cancer: a meta-analysis // Health Psychol. 1999; 18: 520–531.
  33. Miao J. W., Liu L. J., Huang J. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma // Int. J. Oncol. 2014; 45: 165–176.
  34. Oerleman M. E., Van den Akker M., Schuurman A. G. et al. A meta-analysis on depression and subsequent cancer risk // Clin. Pract. Epidemiol. Mental Health. 2007; 3: 29.
  35. Ostuzzi G., Matcham F., Dauchy S. et al. Antidepressants for the treatment of depression in people with cancer // Cochrane Database Syst. Rev. 2018; 4 (4): CD011006.
  36. Peery A. F., Dellon E. S., Lund J. et al. Burden of Gastrointestinal Disease in the United States: 2012 Update // Gastroenterology. 2012; 143 (5): 1179–1187.
  37. Penninx B. W., Guralnik J. M., Pahor M. et al. Chronically depressed mood and cancer risk in older persons // J. Natl. Cancer Inst. 1998; 90: 1888–1893.
  38. Pinquart M., Duberstein P. R. Depression and cancer mortality: a meta-analysis // Psychol. Med. 2010; 40: 1797–810.
  39. Possel P., Adams E., Valentine J. C. Depression as a risk factor for breast cancer: investigating methodological limitations in the literature // Cancer Causes Control. 2012; 23: 1223–1229.
  40. Satin J. R., Linden W., Phillips M. J. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis // Cancer. 2009; 115: 5349–5361.
  41. Scarborough B. M., Smith C. B. Optimal pain management for patients with cancer in the modern era // CA Cancer J. Clin. 2018; 68 (3): 182–196.
  42. Schuller H. M., Al-Wadei H. A., Ullah M. F. et al. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention // Carcinogenesis. 2012; 33: 191–196.
  43. Shan T., Ma J., Ma Q. et al. β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis // Curr. Mol. Med. 2013; 13: 1023–1034.
  44. Sharma R. P., Tun N., Grayson D. R. Depolarization induces downregulation of DNMT1 and DNMT3a in primary cortical cultures // Epigenetics. 2008; 3: 74–80.
  45. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016 // CA Cancer J. Clin. 2016; 66 (1): 7–30.
  46. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression // Biol. Psychiatry. 2003; 54: 269–282.
  47. Tilg H., Dinarello C. A., Mier J. W. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators // Immunol. Today. 1997; 18: 428–432.
  48. Valkanova V., Ebmeier K. P., Allan C. L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies // J. Affect Disord. 2013; 150: 736–744.
  49. Vodermaier A., Linden W., Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments // J. Natl. Cancer Inst. 2009; 101 (21): 1464–88.
  50. Watson M., Haviland J. S., Greer S. et al. Influence of psychological response on survival in breast cancer: a population-based cohort study // Lancet. 1999; 354: 1331–1336.
  51. World Cancer Research Fund. https://www.wcrf.org/cancer-trends/global-cancer-data-by-country (date of access 26.06.2022).
  52. Zhang T., Tan X. L, Xu Y. et al. Expression and prognostic value of indoleamine 2, 3-dioxygenase in pancreatic cancer // Chin. Med. J. (Engl). 2017; 130: 710–716.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*